依照目標分子的大小，評估適用的濾膜孔徑大小，一般以截留分子量 (MWCO, NMWL)或分子直徑表示。濾膜的選擇，通常會選擇目標分子分子量1/3 ~ 1/6的 MWCO，即低於目標分子量的3~6倍，並留意欲分離的分子之間，大小至少應相差10倍以上，以確保混合物有效分離；若以分子直徑選擇濾膜，則選用濾膜孔徑 (um)小於目標分子直徑即可。
濾膜之截留分子量 (MWCO) 有 1k, 3k, 5k, 10k, 30k, 50k, 70k, 100k, 300k, 500k, 1,000k Da，共11種規格可供選擇。
規格：
| Minimate™ tangential flow filtration capsules |
| 濾膜材質 |
Omega™ membrane
(modified polyethersulfone) |
| 有效過濾面積 |
50 cm2 (0.05 ft2) |
| 濾匣大小 |
20 cm × 3.8 cm × 1.8 cm
(8 in. × 1.5 in. × 0.7 in.) |
| 建議掃流速度 |
30-80 mL/min (0.6-1.6 L/min/ft2 ) |
濾膜殘留體積
(Hold-Up Volume) |
1.3 mL |
| 操作溫度範圍 |
5-50°C (41-122°F) |
| 最大操作壓力 |
4 bar (400 kPa, 60 psi) @ 20°C (68°F) |
| 耐受pH範圍 |
2-14 |
應用於外泌體純化
引用文獻
1. A novel approach to alleviate acetaminophen-induced hepatotoxicity with hybrid balloon flower root-derived exosome-like nanoparticles (BDEs) with silymarin via inhibition of hepatocyte MAPK pathway and apoptosis. Cell Commun Signal. 2024 Jun 18;22(1):334. doi: 10.1186/s12964-024-01700-z.
分離桔梗根部衍生之類外泌體奈米粒子(exosome-like nanoparticles, BDEs) <使用500 kDa濾匣>
2. Extracellular Vesicles, as Drug-Delivery Vehicles, Improve the Biological Activities of Astaxanthin. Antioxidants 2023, 12(2), 473: doi.org/10.3390/antiox12020473
胎牛血清衍生外泌體(FBS-derived EVs) <使用300 kDa濾匣>
3. Comparative analysis of tangential flow filtration and ultracentrifugation, both combined with subsequent size exclusion chromatography, for the isolation of small extracellular vesicles. J Extracell Vesicles. 2022 Sep;11(9):e12266. doi: 10.1002/jev2.12266.
在此篇論文中，明確指出使用300kDa之濾匣可有效分離sEVs。
從子宮頸癌細胞株HeLa, 乳癌細胞株MDA‐MB‐231, 老鼠乳癌細胞EO771及老鼠黑色素癌細胞B16F10 之 細胞培養後之條件培養液(conditioned media)分離之外泌體。
4. Isolation and Characterization of Extracellular Vesicle from Mesenchymal Stem Cells of the Epidural Fat of the Spine. Asian Spine J. 2022 Apr;16(2):153-161. doi: 10.31616/asj.2021.0129. Epub 2021 Sep 1.
從椎管内硬膜外脂肪（epidural fat，EF）的MSC中分離出EVs <使用100 kDa(10nm)濾匣>
5. Functional siRNA Delivery by Extracellular Vesicle–Liposome Hybrid Nanoparticles. Adv Healthc Mater. 2022 Mar;11(5):e2101202. doi: 10.1002/adhm.202101202. Epub 2021 Aug 11.
分離cardiac progenitor cell (CPC)-EVs <使用100 kDa濾匣>
6. Reactive oxygen species-responsive dendritic cell-derived exosomes for rheumatoid arthritis. Acta Biomater. 2021 Jul 1:128:462-473. doi: 10.1016/j.actbio.2021.04.026. Epub 2021 Apr 18.
耐受性樹突狀細胞(tolerogenic DC, tolDC)衍生之exosome <使用300 kDa濾匣>
7. A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA. Nat Commun. 2020 Feb 28;11(1):1113. doi: 10.1038/s41467-020-14977-8.
分離MDA-MB-231 sgRNA+細胞之EVs <使用100 kDa濾匣>
8. Microvesicles from brain-extract—treated mesenchymal stem cells improve neurological functions in a rat model of ischemic stroke. Sci Rep. 2016 Sep 9:6:33038. doi: 10.1038/srep33038.
分離human MSCs之microvesicles (MVs) <使用100 kDa濾匣>
Google patent
WO2018004145A1 - Anti-inflammatory composition containing yeast-derived extracellular vesicle
分離酵母菌衍生之外泌體(yeast derived exosomes) <使用100 kDa濾匣>
訂購資訊
| 產品貨號 |
品名及MWCO |
包裝 |
| OA001C12 |
Minimate TFF Capsules with Omega Membrane - 1K |
1/pk |
| OA003C12 |
Minimate TFF Capsules with Omega Membrane - 3K |
1/pk |
| OA005C12 |
Minimate TFF Capsules with Omega Membrane - 5K |
1/pk |
| OA010C12 |
Minimate TFF Capsules with Omega Membrane - 10K |
1/pk |
| OA030C12 |
Minimate TFF Capsules with Omega Membrane - 30K |
1/pk |
| OA050C12 |
Minimate TFF Capsules with Omega Membrane - 50K |
1/pk |
| OA070C12 |
Minimate TFF Capsules with Omega Membrane - 70K |
1/pk |
| OA100C12 |
Minimate TFF Capsules with Omega Membrane - 100K |
1/pk |
| OA300C12 |
Minimate TFF Capsules with Omega Membrane - 300K |
1/pk |
| OA500C12 |
Minimate TFF Capsules with Omega Membrane - 500K |
1/pk |
| OA990C12 |
Minimate TFF Capsules with Omega Membrane - 1000K |
1/pk |